Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for ICI-induced Colitis and Arthritis
NCT03601611Completed
- Sponsor
- Herlev Hospital
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in Colitis and arthritis, sponsored by Herlev Hospital. Primary endpoint: Rate of at least one grade improvement using the NCI CTCAE v5.0 at 2 months. Started Jan 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
Colitisarthritis
Beyond the preview
Go deeper on NCT03601611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601611.